Climb Bio (NASDAQ:CLYM) outlined its strategy and upcoming clinical milestones during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference, with Chief Medical Officer Edgar ...
Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune ...
Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...
Please provide your email address to receive an email when new articles are posted on . Most patients with B-cell lymphomas who relapsed after CAR T-cell therapy responded to the novel, ...
In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is ...
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over ...
Cullinan Therapeutics (NASDAQ:CGEM) executives highlighted upcoming clinical milestones for the company’s two high-priority T-cell engager programs during remarks at the 46th Annual TD Cowen ...
A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results